Occoris inhaler technology to make debut at RDD
Team Consulting will unveil prototype designs using the multi-platform inhaler ‘engine’
Designed primarily for delivering systemic treatments beyond the typically inhaled topical asthma and COPD, such as vaccines, pain relief and insulin, the Occoris ‘engine’ is ultra-small, active and achieves accurate and repeatable delivery of API-only formulations, the firm says.
The Ickleton, Cambridgeshire company will showcase prototypes for a single-use disposable inhaler, a multi-unit dose inhaler and a multi-dose inhaler – demonstrating the technology’s multi-platform credentials, and to illustrate the numerous design possibilities afforded by Occoris.
Team Consulting says it developed the technology after identifying a number of factors that are likely to shape the respiratory drug delivery market of the future.
First, asthma and COPD inhalers typically use an inert carrier fraction to dilute the small quantities of API. Inhalers that treat conditions beyond asthma and COPD will need to deliver a wide range of dosages that do not require a carrier fraction.
Second, inhalers for treating conditions such as diabetes, pain relief or delivering vaccines will require very different designs. Team Consulting says the simplicity and small size (around the same size as a garden pea) of the Occoris engine gives designers flexibility in form factor and materials. For example, one of the concepts on show at RDD will be for mass vaccination and can be produced largely out of recyclable cardboard.
Third, regulators will demand much tighter dose content uniformity, higher delivery efficiencies and better independency of flow rate from inhalers.
Team Consulting says early indications are that inhalers that use the active Occoris engine will deliver highly accurate dosage and repeatable performance.
‘Delivering drug via the pulmonary route offers so many advantages over needles and tablets. The drug is quickly absorbed by the body, in powder form it doesn’t require cold storage and there is no user anxiety or danger of needle-stick injuries,’ says David Harris, head of respiratory drug delivery at Team Consulting.
‘With our Occoris technology we are opening up a wide range of new opportunities beyond the traditional and highly competitive asthma and COPD market, which will help our pharmaceutical clients to establish new revenue streams.’
You may also like
Packaging
To connect or not to connect, that is the question: the need and usability of data should be the deciding factor
Read moreAhead of his session exploring the connectivity of medical devices at Pharmapack Europe 2022 (18-19 May, Paris Expo, Porte de Versailles), the largest hub for the pharma packaging and drug delivery industry, Dr Kevin Robinson speaks to Thomas Watts (TW), Engineering Consultant, Team Consulting
Trending Articles
You may also like
Packaging
To connect or not to connect, that is the question: the need and usability of data should be the deciding factor
Ahead of his session exploring the connectivity of medical devices at Pharmapack Europe 2022 (18-19 May, Paris Expo, Porte de Versailles), the largest hub for the pharma packaging and drug delivery industry, Dr Kevin Robinson speaks to Thomas Watts (TW), Engineering Consultant, Team Consulting
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Sustainability
Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system
A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient safety. The integrated label concept, developed with Schreiner MediPharm, offers reliable first-opening indication, oxygen and light protection, and can include an RFID chip for accurate drug traceability and inventory management. A carton secondary packaging eliminates the need for blister packs, reducing waste and saving valuable storage space in hospitals and during transport, thereby cutting the carbon footprint of the entire value chain by up to 58%